Publications for Anthony Keech
Publications for Anthony Keech
2016
Chia, N., Fulcher, J., Keech, A. (2016).
Beta-blocker, angiotensin-converting enzyme
inhibitor/angiotensin receptor blocker,
nitrate-hydralazine, diuretics, aldosterone
antagonist, ivabradine, devices and digoxin
(BANDAID2): An evidence-based mnemonic for
the treatment of systolic heart failure. Internal
Medicine Journal, 46(6), 653-662. <a
href="http://dx.doi.org/10.1111/imj.12839">[Mo
re Information]</a>
Hague, W., Simes, R., Kirby, A., Keech, A.,
White, H., Hunt, D., Nestel, P., Colquhoun, D.,
Pater, H., Stewart, R., Sullivan, D., et al (2016).
Long-Term Effectiveness and Safety of
Pravastatin in Patients With Coronary Heart
Disease: 16 Years of Follow-Up of the LIPID
Study. Circulation, 133(19), 1851-1860. <a
href="http://dx.doi.org/10.1161/CIRCULATION
AHA.115.018580">[More Information]</a>
Williams, K., Sullivan, D., Veillard, A., O'Brien,
R., George, J., Jenkins, A., Young, S., Ehnholm,
C., Duffield, A., Twigg, S., Keech, A. (2016).
Low alanine aminotransferase levels and higher
number of cardiovascular events in people with
Type 2 diabetes: analysis of the Fenofibrate
Intervention and Event Lowering in Diabetes
(FIELD) study. Diabetic Medicine, 33(3),
356-364. <a
href="http://dx.doi.org/10.1111/dme.12972">[M
ore Information]</a>
Sherrah, A., Andvik, S., van der Linde, D.,
Davies, L., Bannon, P., Padang, R., Vallely, M.,
Wilson, M., Keech, A., Jeremy, R. (2016).
Nonsyndromic Thoracic Aortic Aneurysm and
Dissection: Outcomes With Marfan Syndrome
Versus Bicuspid Aortic Valve Aneurysm.
Journal of the American College of Cardiology,
67(6), 618-626. <a
href="http://dx.doi.org/10.1016/j.jacc.2015.11.03
9">[More Information]</a>
Williams, K., Sullivan, D., Nicholson, G.,
George, J., Jenkins, A., Januszewski, A., Gebski,
V., Manning, P., Tan, Y., Donoghoe, M., Buizen,
L., Twigg, S., Keech, A., et al (2016). Opposite
associations between alanine aminotransferase
and γ-glutamyl transferase levels and all-cause
mortality in type 2 diabetes: Analysis of the
Fenofibrate Intervention and Event Lowering in
Diabetes (FIELD) study. Metabolism: Clinical
and Experimental, 65(5), 783-793. <a
href="http://dx.doi.org/10.1016/j.metabol.2015.1
2.008">[More Information]</a>
Tarnow-Mordi, W., Kirby, A., Juszczak, E.,
Donoghoe, M., Deshpande, S., Morley, C., King,
A., Doyle, L., Fleck, B., Davis, P., Hague, W.,
Gebski, V., Ghadge, A., Keech, A., Simes, R., et
al (2016). Outcomes of two trials of
oxygen-saturation targets in preterm infants. New
England Journal of Medicine, 374(8), 749-760.
<a
href="http://dx.doi.org/10.1056/NEJMoa151421
2">[More Information]</a>
Sabatine, M., Giugliano, R., Keech, A.,
Honarpour, N., Wang, H., Liu, T., Wasserman,
S., Scott, R., Sever, P., Pedersen, T. (2016).
Rationale and design of the Further
cardiovascular OUtcomes Research with PCSK9
Inhibition in subjects with Elevated Risk trial.
American Heart Journal, 173, 94-101. <a
href="http://dx.doi.org/10.1016/j.ahj.2015.11.01
5">[More Information]</a>
Traill, C., Januszewski, A., Larkins, R., Keech,
A., Jenkins, A. (2016). Time to research
Australian female physician-researchers. Internal
Medicine Journal, 46(4), 412-419. <a
href="http://dx.doi.org/10.1111/imj.12986">[Mo
re Information]</a>
Traill, C., Januszewski, A., Larkins, R., Keech,
A., Jenkins, A. (2016). Time to Research
Australian Physician Researchers. Internal
Medicine Journal, 46(5), 550-558. <a
href="http://dx.doi.org/10.1111/imj.13043">[Mo
re Information]</a>
Traill, C., Januszewski, A., Larkins, R., Keech,
A., Jenkins, A. (2016). Time to research
Australian physician-researchers. Internal
Medicine Journal, 46(5), 550-558. <a
href="http://dx.doi.org/10.1111/imj.13043">[Mo
re Information]</a>
2015
Jenkins, A., Joglekar, M., Hardikar, A., Keech,
A., O'Neal, D., Januszewski, A. (2015).
Biomarkers in Diabetic Retinopathy. The Review
of Diabetic Studies, 12(1-2), 159-195. <a
href="http://dx.doi.org/10.1900/RDS.2015.12.15
9">[More Information]</a>
Tonkin, A., Blankenberg, S., Kirby, A., Zeller,
T., Colquhoun, D., Funke-Kaiser, A., Hague, W.,
Hunt, D., Keech, A., Nestel, P., Sullivan, D.,
Simes, R., et al (2015). Biomarkers in stable
coronary heart disease, their modulation and
cardiovascular risk: The LIPID biomarker study.
International Journal of Cardiology, 201,
499-507. <a
href="http://dx.doi.org/10.1016/j.ijcard.2015.07.
080">[More Information]</a>
Sullivan, D., Watts, G., Nicholls, S., Barter, P.,
Grenfell, R., Chow, C., Tonkin, A., Keech, A.
(2015). Clinical Guidelines on Hyperlipidaemia:
Recent Developments, Future Challenges and the
Need for an Australian Review. Heart, Lung and
Circulation, 24(5), 495-502. <a
Publications for Anthony Keech
href="http://dx.doi.org/10.1016/j.hlc.2014.12.00
9">[More Information]</a>
Fulcher, J., O'Connell, R., Voysey, M.,
Emberson, J., Blackwell, L., Mihaylova, B.,
Simes, J., Collins, R., Kirby, A., Colhoun, H.,
Keech, A., et al (2015). Efficacy and safety of
LDL-lowering therapy among men and women:
Meta-analysis of individual data from 174 000
participants in 27 randomised trials. The Lancet,
385(9976), 1397-1405. <a
href="http://dx.doi.org/10.1016/S0140-6736(14)
61368-4">[More Information]</a>
Harmer, J., Keech, A., Veillard, A., Skilton, M.,
Marwick, T., Watts, G., Meredith, I., Celermajer,
D. (2015). Fenofibrate effects on arterial
endothelial function in adults with type 2
diabetes mellitus: A FIELD substudy.
Atherosclerosis, 242(1), 295-302. <a
href="http://dx.doi.org/10.1016/j.atherosclerosis.
2015.07.038">[More Information]</a>
Swerdlow, D., Preiss, D., Kuchenbaecker, K.,
Holmes, M., Engmann, J., Shah, T., Sofat, R.,
Stender, S., Johnson, P., Scott, R., Keech, A., et
al (2015). HMG-coenzyme A reductase
inhibition, type 2 diabetes, and bodyweight:
evidence from genetic analysis and randomised
trials. The Lancet, 385, 351-361. <a
href="http://dx.doi.org/10.1016/S0140-6736(14)
61183-1">[More Information]</a>
Chin, J., Fulcher, J., Jenkins, A., Keech, A.
(2015). Is it Time to Repair a Fairly Fast SAAB
Convertible? Testing an Evidence-based
Mnemonic for the Secondary Prevention of
Cardiovascular Disease. Heart, Lung and
Circulation, 24(5), 480-487. <a
href="http://dx.doi.org/10.1016/j.hlc.2014.11.01
6">[More Information]</a>
Hardikar, A., Satoor, S., Karandikar, M.,
Joglekar, M., Puranik, A., Wong, W., Kumar, S.,
Limaye, A., Bhat, D., Januszewski, A., Keech,
A., Jenkins, A., et al (2015). Multigenerational
Undernutrition Increases Susceptibility to
Obesity and Diabetes that Is Not Reversed after
Dietary Recuperation. Cell Metabolism, 22(2),
312-319. <a
href="http://dx.doi.org/10.1016/j.cmet.2015.06.0
08">[More Information]</a>
Ong, K., Januszewski, A., O'Connell, R., Buizen,
L., Jenkins, A., Xu, A., Sullivan, D., Barter, P.,
Scott, R., Taskinen, M., Rye, K., Keech, A.
(2015). Relationship of fibroblast growth factor
21 with baseline and new on-study microvascular
disease in the Fenofibrate Intervention and Event
Lowering in Diabetes study. Diabetologia, 59(8),
2035-2044. <a
href="http://dx.doi.org/10.1007/s00125-015-365
2-2">[More Information]</a>
Herrmann, M., Sullivan, D., Veillard, A.,
McCorquodale, T., Straub, I., Scott, R., Laakso,
M., Topliss, D., Jenkins, A., Blankenberg, S.,
Keech, A., et al (2015). Serum 25-Hydroxy
Vitamin D: A Predictor of Macrovascular and
Microvascular Complications in Patients With
Type 2 Diabetes. Diabetes Care, 38(3), 521-528.
<a
href="http://dx.doi.org/10.2337/dc14-0180">[M
ore Information]</a>
Ong, K., Januszewski, A., O'Connell, R.,
Jenkins, A., Xu, A., Sullivan, D., Barter, P.,
Hung, W., Scott, R., Taskinen, M., Keech, A.,
Rye, K. (2015). The relationship of fibroblast
growth factor 21 with cardiovascular outcome
events in the Fenofibrate Intervention and Event
Lowering in Diabetes study. Diabetologia, 58(3),
464-473. <a
href="http://dx.doi.org/10.1007/s00125-014-345
8-7">[More Information]</a>
2014
White, H., Tonkin, A., Simes, R., Stewart, R.,
Mann, K., Thompson, P., Colquhoun, D., West,
M., Nestel, P., Sullivan, D., Keech, A., et al
(2014). Association of Contemporary Sensitive
Troponin I Levels at Baseline and Change at 1
Year With Long - Term Coronary Events
Following Myocardial Infarction or Unstable
Angina. Journal of the American College of
Cardiology, 63(4), 345-354. <a
href="http://dx.doi.org/10.1016/j.jacc.2013.08.16
43">[More Information]</a>
Harmer, J., Keech, A., Veillard, A., Skilton, M.,
Marwick, T., Watts, G., Meredith, I., Celermajer,
D. (2014). Cigarette smoking and albuminuria
are associated with impaired arterial smooth
muscle function in patients with type 2 diabetes
mellitus: a FIELD substudy. Diabetes Research
and Clinical Practice, 106(2), 328-336. <a
href="http://dx.doi.org/10.1016/j.diabres.2014.08
.029">[More Information]</a>
d'Emden, M., Jenkins, A., Li, L., Zannino, D.,
Mann, K., Best, J., Stuckey, B., Park, K.,
Saltevo, J., Keech, A. (2014). Favourable effects
of fenofibrate on lipids and cardiovascular
disease in women with type 2 diabetes: results
from the Fenofibrate Intervention and Event
Lowering in Diabetes (FIELD) study.
Diabetologia, 57(11), 2296-2303. <a
href="http://dx.doi.org/10.1007/s00125-014-334
4-3">[More Information]</a>
Waldman, B., Jenkins, A., Davis, T., Taskinen,
M., Scott, R., O'Connell, R., Gebski, V., Ng, M.,
Keech, A. (2014). HDL-C and HDL-C/ApoA-I
Predict Long-Term Progression of Glycemia in
Established Type 2 Diabetes. Diabetes Care,
37(8), 2351-2358. <a
href="http://dx.doi.org/10.2337/dc13-2738">[M
ore Information]</a>
Publications for Anthony Keech
Ding, L., Cheng, R., Hu, Y., Takahashi, Y.,
Jenkins, A., Keech, A., Humphries, K., Gu, X.,
Elliott, M., Xia, X., et al (2014). Peroxisome
Proliferator–Activated Receptor α Protects
Capillary Pericytes in the Retina. The American
Journal of Pathology, 184(10), 2709-2720. <a
href="http://dx.doi.org/10.1016/j.ajpath.2014.06.
021">[More Information]</a>
Chan, K., Simpson, P., Yong, A., Dunn, L.,
Chawantanpipat, C., Hsu, C., Yu, Y., Keech, A.,
Celermajer, D., Ng, M. (2014). The Relationship
between Endothelial Progenitor Cell Populations
and Epicardial and Microvascular Coronary
Disease-A Cellular, Angiographic and
Physiologic Study. PloS One, 9(4), 1-12. <a
href="http://dx.doi.org/10.1371/journal.pone.009
3980">[More Information]</a>
Boekholdt, S., Hovingh, G., Mora, S., Arsenault,
B., Amarenco, P., Pedersen, T., LaRosa, J.,
Waters, D., DeMicco, D., Simes, R., Keech, A.,
et al (2014). Very low levels of atherogenic
lipoproteins and the risk for cardiovascular
events: a meta-analysis of statin trials. Journal of
the American College of Cardiology, 64(5),
485-494. <a
href="http://dx.doi.org/10.1016/j.jacc.2014.02.61
5">[More Information]</a>
2013
Sullivan, T., Duque, G., Keech, A., Herrmann,
M. (2013). An Old Friend in a New Light: The
Role of Osteocalcin in Energy Metabolism.
Cardiovascular Therapeutics (Online), 31(2),
65-75. <a
href="http://dx.doi.org/10.1111/j.1755-5922.201
1.00300.x">[More Information]</a>
the treatment effect of pravastatin: results from
the Long-Term Intervention with Pravastatin in
Ischemic Disease study. Journal of the American
Heart Association, 2(5), 1-12. <a
href="http://dx.doi.org/10.1161/JAHA.113.0003
60">[More Information]</a>
Ting, R., Keech, A. (2013). Fenofibrate and renal
disease: Clinical effects in diabetes. Clinical
Lipidology, 8(6), 669-680. <a
href="http://dx.doi.org/10.2217/clp.13.69">[Mor
e Information]</a>
Simo, R., Roy, S., Behar-Cohen, F., Keech, A.,
Mitchell, P., Wong, T. (2013). Fenofibrate: a
new treatment for diabetic retinopathy.
Molecular mechanisms and future perspectives.
Current Medicinal Chemistry, 20(26),
3258-3266. <a
href="http://dx.doi.org/10.2174/0929867311320
260009">[More Information]</a>
Olver, I., Keech, A. (2013). Forming networks
for research: proposal for an Australian clinical
trials alliance. Medical Journal of Australia,
198(5), 254-255. <a
href="http://dx.doi.org/10.5694/mja12.11067">[
More Information]</a>
Dignan, R., Keech, A., Gebski, V., Mann, K.,
Hughes, C. (2013). Is home warfarin
self-management effective? Results of the
randomised Self-Management of
Anticoagulation Research Trial. International
Journal of Cardiology, 168(6), 5378-5384. <a
href="http://dx.doi.org/10.1016/j.ijcard.2013.08.
054">[More Information]</a>
Noonan, J., Jenkins, A., Ma, J., Keech, A.,
Wang, J., Lamoureux, E. (2013). An Update on
the Molecular Actions of Fenofibrate and Its
Clinical Effects on Diabetic Retinopathy and
Other Microvascular End Points in Patients With
Diabetes. Diabetes, 62(12), 3968-3975. <a
href="http://dx.doi.org/10.2337/db13-0800">[M
ore Information]</a>
Chan, K., O'Connell, R., Sullivan, D., Hoffmann,
L., Rajamani, K., Whiting, M., Donoghoe, M.,
Vanhala, M., Hamer, A., Yu, B., Stocker, R., Ng,
M., Keech, A. (2013). Plasma total bilirubin
levels predict amputation events in type 2
diabetes mellitus: the fenofibrate intervention
and event lowering in diabetes (field) study.
Diabetologia, 56(4), 724-736. <a
href="http://dx.doi.org/10.1007/s00125-012-281
8-4">[More Information]</a>
Ghosh, J., Martin, A., Keech, A., Chan, K.,
Gomes, S., Singarayar, S., McGuire, M. (2013).
Balloon Warming Time Is the Strongest
Predictor Of Late Pulmonary Vein Electrical
Reconnection Following Balloon Cryoablation
for Atrial Fibrillation. Heart Rhythm, 10(9),
1311-1317. <a
href="http://dx.doi.org/10.1016/j.hrthm.2013.06.
014">[More Information]</a>
Hankey, G., Anderson, N., Ting, R., Veillard, A.,
Romo, M., Wosik, M., Sullivan, D., O'Connell,
R., Hunt, D., Keech, A. (2013). Rates and
predictors of risk of stroke and its subtypes in
diabetes: A prospective observational study.
Journal of Neurology, Neurosurgery and
Psychiatry, 84(3), 281-287. <a
href="http://dx.doi.org/10.1136/jnnp-2012-30336
5">[More Information]</a>
White, H., Simes, R., Stewart, R., Blankenberg,
S., Barnes, E., Marschner, I., Thompson, P.,
West, M., Zeller, T., Colquhoun, D., Keech, A.,
Sullivan, D., et al (2013). Changes in
lipoprotein-associated phospholipase A2 activity
predict coronary events and partly account for
Chen, Y., Hu, Y., Lin, M., Jenkins, A., Keech,
A., Mott, R., Lyons, T., Ma, J. (2013).
Therapeutic Effects of PPARα Agonists on
Diabetic Retinopathy in Type 1 Diabetes
Models. Diabetes, 62(1), 261-272. <a
href="http://dx.doi.org/10.2337/db11-0413">[M
Publications for Anthony Keech
ore Information]</a>
2012
Donaghue, K., Keech, A., Craig, M., O'Connell,
P. (2012). A 'cure' for diabetes and its
complications. In Louise A. Baur, Stephen M.
Twigg, Roger S.Magnusson (Eds.), A Modern
Epidemic: Expert Perspectives on Obesity and
Diabetes, (pp. 401-420). Sydney, Australia:
Sydney University Press.
Ting, R., Keech, A., Drury, P., Donoghoe, M.,
Hedley, J., Jenkins, A., Davis, T., Lehto, S.,
Celermajer, D., Simes, R., Rajamani, K., et al
(2012). Benefits and Safety of Long-Term
Fenofibrate Therapy in People With Type 2
Diabetes and Renal Impairment - The FIELD
Study. Diabetes Care, 35(2), 218-225. <a
href="http://dx.doi.org/10.2337/dc11-1109">[M
ore Information]</a>
Tonkin, A., Hunt, D., Voysey, M., Kesaniemi,
Y., Hamer, A., Waites, J., Mahar, L., Mann, S.,
Glasziou, P., Forder, P., Simes, R., Keech, A.
(2012). Effects of fenofibrate on cardiovascular
events in patients with diabetes, with and without
prior cardiovascular disease: The Fenofibrate
Intervention and Event Lowering in Diabetes
(FIELD) study. American Heart Journal, 163(3),
508-514. <a
href="http://dx.doi.org/10.1016/j.ahj.2011.12.00
4">[More Information]</a>
Jun, M., Zhu, B., Tonelli, M., Jardine, M., Patel,
A., Neal, B., Liyanage, T., Keech, A., Cass, A.,
Perkovic, V. (2012). Effects of Fibrates in
Kidney Disease: A Systematic Review and
Meta-Analysis. Journal of the American College
of Cardiology, 60(20), 2061-2071. <a
href="http://dx.doi.org/10.1016/j.jacc.2012.07.04
9">[More Information]</a>
Best, J., Drury, P., Davis, T., Taskinen, M.,
Kesaniemi, Y., Scott, R., Pardy, C., Voysey, M.,
Keech, A. (2012). Glycemic Control Over 5
Years in 4,900 People With Type 2 Diabetes:
Real-world diabetes therapy in a clinical trial
cohort. Diabetes Care, 35(5), 1165-1170. <a
href="http://dx.doi.org/10.2337/dc11-1307">[M
ore Information]</a>
Emberson, J., Kearney, P., Blackwell, L.,
Newman, C., Reith, C., Bhala, N., Holland, L.,
Peto, R., Keech, A., Collins, R., Simes, R., et al
(2012). Lack of effect of lowering LDL
cholesterol on cancer: meta-analysis of
individual data from 175 000 people in 27
randomised trials of statin therapy. PloS One,
7(1), 1-10. <a
href="http://dx.doi.org/10.1371/journal.pone.002
9849">[More Information]</a>
Preiss, D., Tikkanen, M., Welsh, P., Ford, I.,
Lovato, L., Elam, M., laRosa, J., DeMicco, D.,
Colhoun, H., Goldenberg, I., Keech, A., et al
(2012). Lipid-Modifying Therapies and Risk of
Pancreatitis: A Meta-analysis. JAMA, 308(8),
804-811. <a
href="http://dx.doi.org/10.1001/jama.2012.8439"
>[More Information]</a>
Ong, K., Rye, K., O'Connell, R., Jenkins, A.,
Brown, C., Xu, A., Sullivan, D., Barter, P.,
Keech, A. (2012). Long-Term Fenofibrate
Therapy Increases Fibroblast Growth Factor 21
and Retinol-Binding Protein 4 in Subjects with
Type 2 Diabetes. Journal of Clinical
Endocrinology and Metabolism, 97(12),
4701-4708. <a
href="http://dx.doi.org/10.1210/jc.2012-2267">[
More Information]</a>
Herrmann, M., Whiting, M., Veillard, A.,
Ehnholm, C., Sullivan, D., Keech, A. (2012).
Plasma homocysteine and the risk of venous
thromboembolism: Insights from the FIELD
study. Clinical Chemistry and Laboratory
Medicine, 50(12), 2213-2219. <a
href="http://dx.doi.org/10.1515/cclm-2012-0078
">[More Information]</a>
Fulcher, J., Keech, A. (2012). The case for more
intensive use of statins. Therapeutic Advances in
Chronic Diseases, 3(5), 201-210. <a
href="http://dx.doi.org/10.1177/2040622312454
045">[More Information]</a>
Mihaylova, B., Emberson, J., Blackwell, L.,
Keech, A., Simes, R., Barnes, E., Voysey, M.,
Gray, A., Collins, R., Baigent, C., et al (2012).
The effects of lowering LDL cholesterol with
statin therapy in people at low risk of vascular
disease: meta-analysis of individual data from 27
randomised trials. The Lancet, 380(9841),
581-590. <a
href="http://dx.doi.org/10.1016/S0140-6736(12)
60367-5">[More Information]</a>
Ng, M., Yong, A., Ho, M., Shah, M.,
Chawantanpipat, C., O'Connell, R., Keech, A.,
Kritharides, L., Fearon, W. (2012). The Index of
Microcirculatory Resistance Predicts Myocardial
Infarction Related to Percutaneous Coronary
Intervention. Circulation: Cardiovascular
Interventions, 5(4), 515-522. <a
href="http://dx.doi.org/10.1161/CIRCINTERVE
NTIONS.112.969048">[More Information]</a>
Keech, A., Simes, R., Fulcher, J. (2012). The
role of statin therapy in patients with lower
vascular risk. Medical Journal of Australia,
197(3), 130-131. <a
href="http://dx.doi.org/10.5694/mja12.10925">[
More Information]</a>
2011
Sullivan, D., Forder, P., Simes, R., Whiting, M.,
Kritharides, L., Merrifield, A., Donoghoe, M.,
Publications for Anthony Keech
Colman, P., Neil, G., Haapamäki, H., Keech, A.
(2011). Associations between the use of
metformin, sulphonylureas, or diet alone and
cardiovascular outcomes in 6005 patients with
type 2 diabetes in the FIELD study. Diabetes
Research and Clinical Practice, 94(2), 284-290.
<a
href="http://dx.doi.org/10.1016/j.diabres.2011.07
.028">[More Information]</a>
Davis, T., Ting, R., Best, J., Donoghoe, M.,
Drury, P., Sullivan, D., Jenkins, A., O'Connell,
R., Whiting, M., Glasziou, P., Simes, R., Gebski,
V., Keech, A., et al (2011). Effects of fenofibrate
on renal function in patients with type 2 diabetes
mellitus: the Fenofibrate Intervention and Event
Lowering in Diabetes (FIELD) Study.
Diabetologia, 54(2), 280-290. <a
href="http://dx.doi.org/10.1007/s00125-010-195
1-1">[More Information]</a>
Drury, P., Ting, R., Zannino, D., Ehnholm, C.,
Flack, J., Whiting, M., Fassett, R., Ansquer, J.,
Dixon, P., Davis, T., Pardy, C., Keech, A., et al
(2011). Estimated Glomerular Filtration Rate and
Albuminuria are Independent Predictors of
Cardiovascular Events and Death in Type 2
Diabetes Mellitus: The Fenofibrate Intervention
and Event Lowering in Diabetes (FIELD) Study.
Diabetologia, 54(1), 32-43. <a
href="http://dx.doi.org/10.1007/s00125-010-185
4-1">[More Information]</a>
Scott, R., Donoghoe, M., Watts, G., O'Brien, R.,
Pardy, C., Taskinen, M., Davis, T., Colman, P.,
Manning, P., Fulcher, G., Keech, A. (2011).
Impact of metabolic syndrome and its
components on cardiovascular disease event
rates in 4900 patients with type 2 diabetes
assigned to placebo in the FIELD randomised
trial. Cardiovascular Diabetology, 10(1),
102-1-102-8. <a
href="http://dx.doi.org/10.1186/1475-2840-10-1
02">[More Information]</a>
Taskinen, M., Barter, P., Ehnholm, C., Sullivan,
D., Mann, K., Simes, R., Best, J., Hamwood, S.,
Keech, A. (2010). Ability of traditional lipid
ratios and apolipoprotein ratios to predict
cardiovascular risk in people with type 2
diabetes. Diabetologia, 53(9), 1846-1855. <a
href="http://dx.doi.org/10.1007/s00125-010-180
6-9">[More Information]</a>
Davis, T., Ting, R., Best, J., Donoghoe, M.,
Drury, P., Sullivan, D., Jenkins, A., O'Connell,
R., Whiting, M., Glasziou, P., Simes, R., Gebski,
V., Keech, A., et al (2010). Effects of fenofibrate
on renal function in patients with type 2 diabetes
mellitus: the Fenofibrate Intervention and Event
Lowering in Diabetes (FIELD) Study.
Diabetologia, 54(2), 280-290. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=21052978">[More Information]</a>
Baigent, C., Blackwell, L., Emberson, J.,
Holland, L., Reith, C., Bhala, N., Peto, R.,
Barnes, E., Keech, A., Simes, R., et al (2010).
Efficacy and safety of more intensive lowering
of LDL cholesterol: a meta-analysis of data from
170 000 participants in 26 randomised trials. The
Lancet, 376(9753), 1670-1681. <a
href="http://dx.doi.org/10.1016/S0140-6736(10)
61350-5">[More Information]</a>
Burgess, D., Hunt, D., Li, L., Zannino, D.,
Williamson, E., Davis, T., Laakso, M.,
Kesaniemi, Y., Zhang, J., Sy, R., Keech, A., et al
(2010). Incidence and predictors of silent
myocardial infarction in type 2 diabetes and the
effect of fenofibrate: an analysis from the
Fenofibrate Intervention and Event Lowering in
Diabetes (FIELD) study. European Heart
Journal, 31(1), 92-99. <a
href="http://dx.doi.org/10.1093/eurheartj/ehp377
">[More Information]</a>
Hayes, A., Clarke, P., Voysey, M., Keech, A.
(2011). Simulation of Quality-Adjusted Survival
in Chronic Diseases: An Application in Type 2
Diabetes. Medical Decision Making, 31(4),
559-570. <a
href="http://dx.doi.org/10.1177/0272989X11409
049">[More Information]</a>
Chan, K., Chawantanpipat, C., Gattorna, T.,
Chantadansuwan, T., Kirby, A., Madden, A.,
Keech, A., Ng, M. (2010). The relationship
between coronary stenosis severity and
compression type coronary artery movement in
acute myocardial infarction. American Heart
Journal, 159(4), 584-592. <a
href="http://dx.doi.org/10.1016/j.ahj.2009.12.03
6">[More Information]</a>
2010
2009
Simes, R., Voysey, M., O'Connell, R., Glasziou,
P., Best, J., Scott, R., Pardy, C., Byth Wilson, K.,
Sullivan, D., Ehnholm, C., Keech, A. (2010). A
novel method to adjust efficacy estimates for
uptake of other active treatments in long-term
clinical trials. PloS One, 5(1), e8580-1-e8580-10.
<a
href="http://dx.doi.org/10.1371/journal.pone.000
8580">[More Information]</a>
Keech, A., Horowitz, J. (2009).
Cost-effectiveness Considerations of
Cardiovascular Therapeutics. Heart, Lung and
Circulation, 18(2), 118-122. <a
href="http://dx.doi.org/10.1016/j.hlc.2008.11.00
6">[More Information]</a>
Rajamani, K., Coleman, P., Li, L., Best, J.,
Voysey, M., D'Emden, M., Laakso, M., Baker,
J., Keech, A., FIELD study investigators, F.
Publications for Anthony Keech
(2009). Effect of fenofibrate on amputation
events in people with type 2 diabetes mellitus
(FIELD study): a prespecified analysis of a
randomised controlled trial. The Lancet,
373(9677), 1780-1788. <a
href="http://dx.doi.org/10.1016/S0140-6736(09)
60698-X">[More Information]</a>
Scott, R., O'Brien, R., Fulcher, G., Pardy, C.,
D'Emden, M., Boey (Tse), D., Taskinen, M.,
Ehnholm, C., Keech, A., FIELD study
investigators, F. (2009). Effects of Fenofibrate
Treatment on Cardiovascular Disease Risk in
9,795 Individuals With Type 2 Diabetes and
Various Components of the Metabolic
Syndrome: The Fenofibrate Intervention and
Event Lowering in Diabetes (FIELD) study.
Diabetes Care, 32(3), 493-498. <a
href="http://dx.doi.org/10.2337/dc08-1543">[M
ore Information]</a>
Soderberg, S., Colquhoun, D., Keech, A., Yallop,
J., Barnes, E., Pollicino, C., Simes, R., Tonkin,
A., Nestel, P. (2009). Leptin, but not adiponectin,
is a predictor of recurrent cardiovascular events
in men: results from the LIPID study.
International Journal of Obesity, 33(1), 123-130.
<a
href="http://dx.doi.org/10.1038/ijo.2008.224">[
More Information]</a>
Taskinen, M., Sullivan, D., Ehnholm, C.,
Whiting, M., Zannino, D., Simes, R., Keech, A.,
Barter, P. (2009). Relationships of HDL
cholesterol, ApoA-I, and ApoA-II with
homocysteine and creatinine in patients with
Type 2 diabetes treated with fenofibrate.
Arteriosclerosis, Thrombosis, and Vascular
Biology, 29(6), 950-955. <a
href="http://dx.doi.org/10.1161/ATVBAHA.108.
178228">[More Information]</a>
Clarke, P., Hayes, A., Glasziou, P., Scott, R.,
Simes, R., Keech, A. (2009). Using the EQ-5D
index score as a predictor of outcomes in patients
with type 2 diabetes. Medical Care, 47(1), 61-68.
<a
href="http://dx.doi.org/10.1097/MLR.0b013e318
1844855">[More Information]</a>
2008
Cook, D., Keech, A., Gebski, V., Pike, R.,
Wonders, S. (2008). Balancing the outcomes:
reporting harms (adverse events). In Anthony
Keech, Val Gebski, Rhana Pike (Eds.),
Interpreting and reporting clinical trials: a guide
to the CONSORT statement and the principles of
randomised controlled trials, (pp. 132-142).
Sydney: AMPCo.
Hayes, A., Clarke, P., Glasziou, P., Simes, R.,
Drury, P., Keech, A. (2008). Can self-rated
health scores be used for risk prediction in
patients with type 2 diabetes? Diabetes Care,
31(4), 795-797. <a
href="http://dx.doi.org/10.2337/dc07-1391">[M
ore Information]</a>
Kearney, P., Blackwell, L., Collins, R., Keech,
A., Simes, R., Peto, R., Armitage, J., Baigent, C.
(2008). Efficacy of cholesterol-lowering therapy
in 18 686 people with diabetes in 14 randomised
trials of statins: a meta-analysis. The Lancet, 371,
117-125. <a
href="http://dx.doi.org/10.1016/S0140-6736(08)
60104-X">[More Information]</a>
Keech, A., Mitchell, P., Summanen, P., Davis,
T., Simes, R. (2008). Fenofibrate and diabetic
retinopathy - author's reply. The Lancet, 371,
722.
Keech, A., Mitchell, P., Summanen, P., Davis,
T., Simes, R. (2008). Fenofibrate and diabetic
retinopathy - Authors' reply. The Lancet,
371(9614), 722-722.
Keech, A., Mitchell, P. (2008). FIELD Study
Revealed Fenofibrate Reduced Need for Laser
Treatment for Diabetic Retinopathy. Review of
Endocrinology.
Hiukka, A., Westerbacka, J., Leinonen, E.,
Watanabe, H., Wiklund, O., Hulten, L., Salonen,
J., Tuomainen, T., Yki-Järvinen, H., Keech, A.,
et al (2008). Long-term effects of fenofibrate on
carotid intima-media thickness and augmentation
index in subjects with type 2 diabetes mellitus.
Journal of the American College of Cardiology,
52(25), 2190-2197. <a
href="http://dx.doi.org/10.1016/j.jacc.2008.09.04
9">[More Information]</a>
Lambert, G., Ancellin, N., Charlton, F., Comas,
D., Pilot, J., Keech, A., Patel, S., Sullivan, D.,
Cohn, J., Rye, K., Barter, P. (2008). Plasma
PCSK9 Concentrations Correlate with LDL and
Total Cholesterol in Diabetic Patients and Are
Decreased by Fenofibrate Treatment. Clinical
Chemistry, 54(6), 1038-1045. <a
href="http://dx.doi.org/10.1373/clinchem.2007.0
99747">[More Information]</a>
Kearney, P., Keech, A., Simes, R., Collins, R.
(2008). Statins and diabetes: authors' reply. The
Lancet, 371(9626), 1752-1752.
2007
Scott, R., D'Emden, M., Best, J., Drury, P.,
Ehnholm, C., Kesaniemi, Y., Pardy, C., Tse, D.,
Barter, P., Taskinen, M., Copt, S., Keech, A., et
al (2007). Abstract 3691: Features Of Metabolic
Syndrome Identify Individuals With Type 2
Diabetes Mellitus At High Risk For
Cardiovascular Events And Greater Absolute
Benefits Of Fenofibrate. Circulation, 116,
II_838.
Keech, A., Gebski, V., Forder, P. (2007).
Publications for Anthony Keech
Allocation concealment and blinding: when
ignorance is bliss. In Anthony Keech, Val
Gebski, Rhana Pike (Eds.), Interpreting and
reporting clinical trials: a guide to the
CONSORT statement and the principles of
randomised controlled trials, (pp. 54-64).
Sydney: AMPCo.
Gebski, V., Keech, A., Simes, R. (2007).
Applying subgroup analysis to individual patient
decisions. In Anthony Keech, Val Gebski,
Rhana Pike (Eds.), Interpreting and reporting
clinical trials: a guide to the CONSORT
statement and the principles of randomised
controlled trials, (pp. 114-122). Sydney:
AMPCo.
Keech, A., Gebski, V., Burgess, D. (2007).
Baseline data in clinical trials. In Anthony
Keech, Val Gebski, Rhana Pike (Eds.),
Interpreting and reporting clinical trials: a guide
to the CONSORT statement and the principles of
randomised controlled trials, (pp. 86-91).
Sydney: AMPCo.
Marschner, I., Simes, R., Keech, A. (2007).
Biases in the Identification of Risk Factor
Thresholds and J-Curves. American Journal of
Epidemiology, 166(7), 824-831. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=17644824">[More Information]</a>
Davis, W., Davis, T., Keech, A. (2007).
Calculating cardiovascular risk in people with
diabetes. Diabetes Management Journal,
18(March), 32-32.
Banks, E., Redman, S., Jorm, L., Armstrong, B.,
Bauman, A., Beard, J., Bowles, H., Butow, P.,
Cardona-Morrell, M., Clarke, J., Cowie, C.,
Cumming, R., Fragar, L., Keech, A., Kendig, H.,
Kricker, A., Morgan, G., Nutbeam, D., Quine, S.,
Salkeld, G., et al (2007). Cohort Profile the 45
and Up Study. International Journal of
Epidemiology, September 2007, 1-6.
Keech, A., Gebski, V., Kirby, A. (2007).
Determining the sample size in a clinical trial.
In Anthony Keech, Val Gebski, Rhana Pike
(Eds.), Interpreting and reporting clinical trials:
a guide to the CONSORT statement and the
principles of randomised controlled trials, (pp.
28-38). Sydney: AMPCo.
Keech, A., Mitchell, P., Summanen, P., O'Day,
J., Davis, T., Moffitt, M., Taskinen, M., Simes,
R., Tse, D., Williamson, E., Merrifield, A.,
O'Connell, R., et al (2007). Effect of fenofibrate
on the need for laser treatment for diabetic
retinopathy (FIELD study): a randomised
controlled trial. The Lancet, 370(9600),
1687-1697. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=17988728">[More Information]</a>
Keech, A., Gebski, V., Vachan, B. (2007). Flow
of participants in randomised studies. In
Anthony Keech, Val Gebski, Rhana Pike (Eds.),
Interpreting and reporting clinical trials: a guide
to the CONSORT statement and the principles of
randomised controlled trials, (pp. 72-78).
Sydney: AMPCo.
Keech, A., Seale, J., Gebski, V. (2007).
Generalising the results of trials to clinical
practice. In Anthony Keech, Val Gebski, Rhana
Pike (Eds.), Interpreting and reporting clinical
trials: a guide to the CONSORT statement and
the principles of randomised controlled trials,
(pp. 149-153). Sydney: AMPCo.
Keech, A., Gebski, V., Heritier, S. (2007).
Inclusion of patients in clinical trial analysis: the
intention-to-treat principle. In Anthony Keech,
Val Gebski, Rhana Pike (Eds.), Interpreting and
reporting clinical trials: a guide to the
CONSORT statement and the principles of
randomised controlled trials, (pp. 92-98).
Sydney: AMPCo.
Keech, A., Gebski, V., Pike, R. (2007).
Interpreting and reporting clinical trials: a guide
to the CONSORT statement and the principles of
randomised controlled trials. Sydney: AMPCo.
Keech, A., Pike, R., Granger, R., Gebski, V.
(2007). Interpreting the results of a clinical trial.
Medical Journal of Australia, 186(9), 318-319.
<a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=17371216">[More Information]</a>
Keech, A., Gebski, V., Pike, R., Granger, R.
(2007). Interpreting the results of a clinical trial.
In Anthony Keech, Val Gebski, Rhana Pike
(Eds.), Interpreting and reporting clinical trials:
a guide to the CONSORT statement and the
principles of randomised controlled trials, (pp.
143-148). Sydney: AMPCo.
Keech, A., Ghersi, D., Gebski, V., Pike, R.
(2007). Introducing the report of a randomised
controlled trial: the title, abstract, scientific
background and rationale. In Anthony Keech,
Val Gebski, Rhana Pike (Eds.), Interpreting and
reporting clinical trials: a guide to the
CONSORT statement and the principles of
randomised controlled trials, (pp. 8-10). Sydney:
AMPCo.
Hiukka, A., Leinonen, E., Jauhiainen, M.,
Sundvall, J., Ehnholm, C., Keech, A., Taskinen,
M. (2007). Long-term effects of fenofibrate on
VLDL and HDL subspecies in participants with
type 2 diabetes mellitus. Diabetologia, 50(10),
2067-2075. <a
href="http://dx.doi.org/10.1007/s00125-007-075
Publications for Anthony Keech
1-8">[More Information]</a>
O'Connell, R., Gebski, V., Keech, A. (2007).
Making sense of trial results: outcomes and
estimation. In Anthony Keech, Val Gebski,
Rhana Pike (Eds.), Interpreting and reporting
clinical trials: a guide to the CONSORT
statement and the principles of randomised
controlled trials, (pp. 99-104). Sydney: AMPCo.
Keech, A., Gebski, V. (2007). Managing the
resource demand of a large sample in clinical
trials: can you succeed with fewer subjects? In
Anthony Keech, Val Gebski, Rhana Pike (Eds.),
Interpreting and reporting clinical trials: a guide
to the CONSORT statement and the principles of
randomised controlled trials, (pp. 39-45).
Sydney: AMPCo.
Keech, A., Gebski, V., Lord, S. (2007). Multiple
analyses in clinical trials: sound science or data
dredging? In Anthony Keech, Val Gebski,
Rhana Pike (Eds.), Interpreting and reporting
clinical trials: a guide to the CONSORT
statement and the principles of randomised
controlled trials, (pp. 123-131). Sydney:
AMPCo.
Wilcken, N., Gebski, V., Pike, R., Keech, A.
(2007). Putting results of a clinical trial into
perspective. Medical Journal of Australia,
186(7), 368-370. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=17407436">[More Information]</a>
Wilcken, N., Gebski, V., Pike, R., Keech, A.
(2007). Putting results of a clinical trial into
perspective. In Anthony Keech, Val Gebski,
Rhana Pike (Eds.), Interpreting and reporting
clinical trials: a guide to the CONSORT
statement and the principles of randomised
controlled trials, (pp. 154-161). Sydney:
AMPCo.
Beller, E., Gebski, V., Keech, A. (2007).
Randomisation in clinical trials. In Anthony
Keech, Val Gebski, Rhana Pike (Eds.),
Interpreting and reporting clinical trials: a guide
to the CONSORT statement and the principles of
randomised controlled trials, (pp. 46-53).
Sydney: AMPCo.
Gebski, V., Beller, E., Keech, A., Van Der
Weyden, M. (2007). Randomised Controlled
Trials: Elements of a Good Study. In Anthony
Keech, Val Gebski, Rhana Pike (Eds.),
Interpreting and reporting clinical trials: a guide
to the CONSORT statement and the principles of
randomised controlled trials, (pp. 7-22). Sydney:
AMPCo.
Keech, A., Gebski, V., Beller, E., Van Der
Weyden, M. (2007). Randomised controlled
trials: elements of a good study. In Anthony
Keech, Val Gebski, Rhana Pike (Eds.),
Interpreting and reporting clinical trials: a guide
to the CONSORT statement and the principles of
randomised controlled trials, (pp. 1-7). Sydney:
AMPCo.
Hague, W., Keech, A., Gebski, V., Pike, R.
(2007). Recruitment to randomised studies. In
Anthony Keech, Val Gebski, Rhana Pike (Eds.),
Interpreting and reporting clinical trials: a guide
to the CONSORT statement and the principles of
randomised controlled trials, (pp. 78-85).
Sydney: AMPCo.
Keech, A., Gebski, V. (2007). Selecting
participants for clinical trials. In Anthony
Keech, Val Gebski, Rhana Pike (Eds.),
Interpreting and reporting clinical trials: a guide
to the CONSORT statement and the principles of
randomised controlled trials, (pp. 11-15).
Sydney: AMPCo.
Brighton, J., Gebski, V., Keech, A. (2007).
Specifying intervention in a clinical trial. In
Anthony Keech, Val Gebski, Rhana Pike (Eds.),
Interpreting and reporting clinical trials: a guide
to the CONSORT statement and the principles of
randomised controlled trials, (pp. 16-20).
Sydney: AMPCo.
Keech, A., Gebski, V., Marschner, I. (2007).
Specifying objectives and outcomes for clinical
trials. In Anthony Keech, Val Gebski, Rhana
Pike (Eds.), Interpreting and reporting clinical
trials: a guide to the CONSORT statement and
the principles of randomised controlled trials,
(pp. 21-26). Sydney: AMPCo.
Keech, A., Gebski, V. (2007). Statistical methods
in clinical trials. In Anthony Keech, Val
Gebski, Rhana Pike (Eds.), Interpreting and
reporting clinical trials: a guide to the
CONSORT statement and the principles of
randomised controlled trials, (pp. 65-71).
Sydney: AMPCo.
Cook, D., Keech, A., Gebski, V. (2007).
Subgroup analysis in clinical trials. In Anthony
Keech, Val Gebski, Rhana Pike (Eds.),
Interpreting and reporting clinical trials: a guide
to the CONSORT statement and the principles of
randomised controlled trials, (pp. 105-113).
Sydney: AMPCo.
Wilcken, N., Gebski, V., Keech, A., Pike, R.
(2007). Words, Words, Words. Medical Journal
of Australia, 187(4), 256-256.
2006
Keech, A. (2006). Challenges in undertaking
primary prevention trials. 54th Annual Scientific
Meeting of the Cardiac Society of Australian and
New Zealand.
Keech, A., Simes, R. (2006). Clinical trial design
Publications for Anthony Keech
& management: The role of PPAR-ALPHA
agonists in prevention of CVD. Atherosclerosis
Supplements, 7(3), 174-174.
Keech, A., Simes, R., Barter, P., Best, J., Scott,
R., Taskinen, M. (2006). Correction to the
FIELD study report. The Lancet, 368(9545),
1415. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=17055933">[More Information]</a>
Keech, A. (2006). Effects of long-term
fenofibrate therapy in the FIELD study. Meeting
of the Taiwan Endocrine Society.
Keech, A. (2006). Effects of long-term
fenofibrate therapy on cardiovascular events
among 9795 people with type 2 diabetes
mellitus: The FIELD study, a randomised
controlled trial. XIV International Symposium on
Atherosclerosis, Ireland: Elsevier Ireland Ltd.
Baigent, C., Keech, A., Kearney, P., Collins, R.,
Simes, R. (2006). Efficacy and safety of
cholesterol-lowering treatment - Reply. The
Lancet, 367(9509), 470-471.
Baigent, C., Keech, A., Kearney, P., Collins, R.,
Simes, R. (2006). Efficacy and safety of
cholesterol-lowering treatment-authors' reply
[letter]. The Lancet, 367(9509), 470-471.
Keech, A., Best, J. (2006). Highlights from the
FIELD trial: a landmark trial. Annual Scientific
Sessions of the American Diabetes Association.
Sullivan, D., Forder, P., Simes, R., Whiting, M.,
Keech, A. (2006). Individual and combined
effects of fenofibrate and sulphonylureas on
HDL cholesterol and outcomes. XIV
International Symposium on Atherosclerosis,
Ireland: Elsevier Ireland Ltd.
Alexander, K., Newby, L., Bhapkar, M., White,
H., Hochman, J., Pfisterer, M., Moliterno, D.,
Peterson, E., Van de Werf, F., Simes, R., Keech,
A., et al (2006). International variation in
invasive care of the elderly with acute coronary
syndromes. European Heart Journal, 27(13),
1558-1564. <a
href="http://dx.doi.org/10.1093/eurheartj/ehl067
">[More Information]</a>
Burgess, D., Kilborn, M., Keech, A. (2006).
Interventions for prevention of post-operative
atrial fibrillation and its complications after
cardiac surgery: a meta-analysis. European
Heart Journal, 27(23), 2846-2857. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=17015402">[More Information]</a>
Keech, A. (2006). Issues in clinical trial design
and management: example of the role of
PPAR-alpha agonists in prevention of CVD,
satellite symposium. XIV International
Symposium on Atherosclerosis, Ireland: Elsevier
Ireland Ltd.
Keech, A. (2006). Metabolic syndrome and
diabetes. NHLBI National Cholesterol Education
Program (USA).
Grieve, S., Ansquer, J., Keech, A. (2006).
Micronized fenofibrate: A useful choice for the
correction of dyslipidemia in metabolic
syndrome and Type 2 diabetes. Future
Cardiology, 2(6), 635-646.
Colquhoun, D., Soderberg, S., Kirby, A., Keech,
A., Simes, R., Hague, W., Hamilton-Craig, I.,
Tonkin, A. (2006). Obesity and adipokines as
risk factors for major coronary heart disease
events in patients with CHD: Results from the
lipid trial. XIV International Symposium on
Atherosclerosis, Ireland: Elsevier Ireland Ltd.
Hiukka, A., Leinonen, E., Hilden, H.,
Perttunen-Nio, H., Keech, A., Taskinen, M.
(2006). Reduction of large VLDL particles by
fenofibrate is associated with reduction of small
dense LDL in type 2 diabetes: Field Helsinki
substudy. XIV International Symposium on
Atherosclerosis, Ireland: Elsevier Ireland Ltd.
Keech, A. (2006). Role of PPAR-alpha agonists
in diabetic disease. Metabolic Syndrome Institute
Meeting.
Gebski, V., Lagleva, M., Keech, A., Simes, R.,
Langlands, A. (2006). Survival Effects of
Postmastectomy Adjuvant Radiation Therapy
Using Biologically Equivalent Doses: A Clinical
Perspective - [Response]. Journal of the National
Cancer Institute, 98(17), 1021-1022.
Gebski, V., Lagleva, M., Keech, A., Simes, R.,
Langlands, A. (2006). Survival effects of
postmastectomy adjuvant radiation therapy using
biologically equivalent doses: a clinical
perspective. Journal of the National Cancer
Institute, 98(1), 26-38. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=16391369">[More Information]</a>
Keech, A., Simes, R., Barter, P., Best, J., Scott,
R., Taskinen, M. (2006). The FIELD study Reply. The Lancet, 367(9517), 1142-1143.
Keech, A. (2006). To manage diabetes:
management in the early stages. Solvay Scientific
Meeting.
2005
Gebski, V., Lagleva, M., Simes, R., Keech, A.,
Langlands, A. (2005). Adjuvant Radiotherapy in
Early Breast Cancer: The Clinical Utility of
Published Meta-Analysis. RANZCR, 55th Annual
Scientific Meeting.
Forder, P., Gebski, V., Keech, A. (2005).
Allocation concealment and blinding [reply].
Publications for Anthony Keech
Medical Journal of Australia, 183(3), 165-166.
Forder, P., Gebski, V., Keech, A. (2005).
Allocation concealment and blinding: when
ignorance is bliss. Medical Journal of Australia,
182(2), 87-89. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=15651970">[More Information]</a>
McAvoy, B., Fulcher, G., Amerena, J., Conner,
G., Beltrame, J., Hankey, G., Keech, A., Lloyd,
B., Neale, M., Pollock, C., et al (2005). An
evidence based clinical aid for cardiovascular
disease--what do GPs think? Australian Family
Physician, 34(4), 297-298. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=15861759">[More Information]</a>
Gebski, V., Heritier, S., Pillai, A., Luke, V.,
Simes, R., Keech, A. (2005). Computer
modelling of adaptive randomisation schemes in
large scale randomised controlled trials. 20th
International Workshop on Statistical Modelling,
Sydney, Australia: University of Western
Sydney.
Briffa, T., Eckermann, S., Griffiths, A., Harris,
P., Heath, M., Freedman, B., Donaldson, L.,
Briffa, N., Keech, A. (2005). Cost-effectiveness
of rehabilitation after an acute coronary event: a
randomised controlled trial. Medical Journal of
Australia, 183(9), 450-455. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=16274344">[More Information]</a>
Keech, A. (2005). Developing evidence-based
practice in Diabetes care: FIELD, a Landmark
Trial. American Diabetes Association 2005.
Tonelli, M., Keech, A., Shepherd, J., Sacks, F.,
Tonkin, A., Packard, C., Pfeffer, M., Simes, R.,
Isles, C., Furberg, C., et al (2005). Effect of
pravastatin in people with chronic kidney disease
and diabetes mellitus. Hypertension, 46(4),
900-901.
Tonelli, M., Keech, A., Shepherd, J., Sacks, F.,
Tonkin, A., Packard, C., Pfeffer, M., Simes, R.,
Isles, C., Furberg, C., et al (2005). Effect of
pravastatin in people with diabetes and chronic
kidney disease. Journal of the American Society
of Nephrology, 16(12), 3748-3754. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=16251235">[More Information]</a>
Keech, A., Simes, R., Barter, P., Best, J., Scott,
R., Taskinen, M., Forder, P., Pillai, A., Davis, T.,
Glasziou, P., Sullivan, D., MacMahon, S., et al
(2005). Effects of long-term fenofibrate therapy
on cardiovascular events in 9795 people with
type 2 diabetes mellitus (the FIELD study):
randomised controlled trial. The Lancet,
366(9500), 1849. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=16310551">[More Information]</a>
Baigent, C., Keech, A., Kearney, P., Blackwell,
L., Buck, G., Pollicino, C., Kirby, A., Sourjina,
T., Peto, R., Collins, R., Simes, R. (2005).
Efficacy and safety of cholesterol-lowering
treatment: prospective meta-analysis of data
from 90,056 participants in 14 randomised trials
of statins. The Lancet, 366(9493), 1267-1278. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=16214597">[More Information]</a>
Scott, R., Best, J., Forder, P., Taskinen, M.,
Simes, R., Barter, P., Keech, A. (2005).
Fenofibrate Intervention and Event Lowering in
Diabetes (FIELD) study: baseline characteristics
and short-term effects of fenofibrate
(ISRCTN64783481). Cardiovascular
Diabetology, 4(13), 1-9. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=16111499">[More Information]</a>
Keech, A. (2005). FIELD study: a large scale
trial of fibrate therapy in diabetes. ASEAN
Federation of Endocrine Societies.
Lundman, P., Keech, A., Griffiths, K., Pillai, A.,
Celermajer, D. (2005). New carotid plaque
formation is very common in adult patients with
Type 2 diabetes mellitus. Diabetic Medicine,
22(3), 355-356. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=15717891">[More Information]</a>
Keech, A. (2005). The long-term efficacy and
safety of Fenofibrate therapy to prevent
cardiovascular events in 9795 people with type 2
diabetes mellitus: the main results of the FIELD
study. American Heart Association Annual
Scientific Sessions.
Keech, A., Grieve, S., Patel, A., Griffiths, K.,
Skilton, M., Watts, G., Marwick, T., Groshens,
M., Celermajer, D. (2005). Urinary albumin
levels in the normal range determine arterial wall
thickness in adults with Type 2 diabetes: a
FIELD substudy. Diabetic Medicine, 22(11),
1558-1565. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=16241922">[More Information]</a>
2004
Keech, A., Wonders, S., Cook, D., Gebski, V.
(2004). Balancing the outcomes: reporting
adverse events. Medical Journal of Australia,
181(4), 215-218.
Publications for Anthony Keech
Collins, R., Armitage, J., Parish, S., Sleight, P.,
Peto, R., Meade, T., Youngman, L., Buxton, M.,
de Bono, D., George, C., Keech, A., Lindley, R.,
et al (2004). Effects of cholesterol-lowering with
simvastatin on stroke and other major vascular
events in 20 536 people with cerebrovascular
disease or other high-risk conditions. The Lancet,
363(9411), 757-767.
Keech, A. (2004). Effects of fenofibrate on lipid
parameters in Type 2 Diabetes: a large-scale trial
to prevent cardiovascular disease. 40th Annual
Meeting of the EASD.
Colquhoun, D., Keech, A., Hunt, D., Marschner,
I., Simes, R., Glasziou, P., White, H., Barter, P.,
Tonkin, A. (2004). Effects Of Pravastatin On
Coronary Events In 2073 Patients With Low
Levels Of Both Low-Density Lipoprotein
Cholesterol And High-Density Lipoprotein
Cholesterol: Results From The Lipid Study.
European Heart Journal, 25(9), 771-777. <a
href="http://dx.doi.org/10.1016/j.ehj.2004.03.01
3">[More Information]</a>
Seale, J., Gebski, V., Keech, A. (2004).
Generalising the results of trials to clinical
practice. Medical Journal of Australia, 181(10),
558-560.
Subgroup analysis: application to individual
patient decisions. Medical Journal of Australia,
180(9), 467-469. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=15115428">[More Information]</a>
Barter, P., Best, J., Colman, P., D'Emden, M.,
Davis, T., Drury, P., Ehnholm, C., Glasziou, P.,
Hunt, D., Keech, A., Forder, P., Simes, R., et al
(2004). The need for a large-scale trial of fibrate
therapy in diabetes: the rationale and design of
the Fenofibrate Intervention and Event Lowering
in Diabetes (FIELD) study. Cardiovascular
Diabetology, 3(December), 9 - 1-9 - 11.
2003
Sniderman, A., Furberg, C., Keech, A., Roeters
van Lennep, J., Frohlich, J., Jungner, I.,
Walldius, G. (2003). Apolipoproteins versus
lipids as indices of coronary risk and as targets
for statin treatment. The Lancet, 361(9359),
777-780.
Burgess, D., Gebski, V., Keech, A. (2003).
Baseline data in clinical trials. Medical Journal
of Australia, 11, 105-107.
O'Connell, R., Gebski, V., Keech, A. (2004).
Making Sense Of Trial Results: Outcomes And
Estimation. Medical Journal of Australia,
180(3), 128-130.
Pike, R., Keech, A., Simes, R. (2003). Clinical
trials research in the new millennium: the
International Clinical Trials Symposium,
Sydney, 21-23 October 2002. Medical Journal of
Australia, 178(7), 316-317.
Lord, S., Gebski, V., Keech, A. (2004). Multiple
Analyses In Clinical Trials: Sound Science Or
Data Dredging? Medical Journal of Australia,
181(8), 452-454.
Kirby, A., Gebski, V., Keech, A. (2003).
Determining the sample size in a clinical trial [in
reply]. Medical Journal of Australia, 178(7),
358-358.
Keech, A. (2004). PBAC review of eligibility
criteria for lipid lowering drugs.
Vachan, B., Gebski, V., Keech, A. (2003). Flow
of participants in randomised studies. Medical
Journal of Australia, 178, 347-349.
Keech, A. (2004). Rationale for a large-scale trial
of fenofibrate to prevent cardiovascular disease
in Type 2 Diabetes. Fournier Symposium;
Taiwan Endocrinology & Diabetes Association
Meeting.
Heritier, S., Gebski, V., Keech, A. (2003).
Inclusion of patients in clinical trial analysis: the
intention-to-treat principle. Medical Journal of
Australia, 11, 438-440.
Keech, A., Best, J., Scott, R., Barter, P., Simes,
R., Forder, P., Taskinen, M., FIELD study
investigators, F. (2004). Significant lipid changes
in a large-scale trial of fenofibrate to prevent
cardiovascular disease in type 2 diabetes.
Journal of the American College of Cardiology,
43(5), A462-A462.
Keech, A. (2004). Significant lipid changes with
fenofibrate in Type 2 Diabetes in a large-scale
trial to prevent cardiovascular disease. APSAVD
Meeting.
Cook, D., Gebski, V., Keech, A. (2004).
Subgroup analysis in clinical trials. Medical
Journal of Australia, 180(6), 289-291.
Simes, R., Gebski, V., Keech, A. (2004).
Keech, A. (2003). Logistics of large scale studies
in diabetes and vascular studies – FIELD & HPS.
Australian Nurses Cardiovascular &
Hypertension Association.
Keech, A., Gebski, V. (2003). Managing the
resource demands of a large sample size in
clinical trials: can you succeed with fewer
subjects. Medical Journal of Australia, 178(7),
356-357.
Collins, R., Armitage, J., Parish, S., Sleight, P.,
Peto, R., Meade, T., Youngman, L., Buxton, M.,
de Bono, D., George, C., Keech, A., et al (2003).
MRC/BHF Heart Protection Study of
cholesterol-lowering with Simvastatin in 5963
people with diabetes: a randomised
placebo-controlled trial. The Lancet, 361(9374),
Publications for Anthony Keech
2005-2016.
Medical Journal of Australia, , 256-257.
Fulcher, G., Amerena, J., Conner, G., Beltrame,
J., Hankey, G., Keech, A., Lloyd, B., McAvoy,
B., Neale, M., Pollock, C., et al (2003).
Prevention of cardiovascular disease: an
evidence-based clinical aid. MJA Focus, (21 July
2003), 1-14.
Neal, B., MacMahon, S., Ohkubo, T., Tonkin,
A., Wilcken, D., Keech, A. (2002).
Dose-dependent effects of folic acid on plasma
homocysteine in a randomized trial conducted
among 723 individuals with coronary heart
disease. European Heart Journal, 23(19),
1509-1515.
Hague, W., Gebski, V., Keech, A. (2003).
Recruitment to randomised studies. Medical
Journal of Australia, 178(11), 579-581.
Keech, A., Colquhoun, D., Best, J., Kirby, A.,
Simes, R., Hunt, D., Hague, W., Beller, E.,
Arulchelvam, M., Baker, J., et al (2003).
Secondary prevention of cardio vascular events
with long-term Pravastatin in patients with
diabetes or impared fasting glucose: results from
the LIPID trial. Diabetes Care, 26(10),
2713-2721.
Gebski, V., Keech, A. (2003). Statistical methods
in clinical trials. Medical Journal of Australia,
11, 182-184.
Keech, A. (2003). The Heart Protection Study:
Results and clinical implications for treatment of
patients in the Asia-Pacific and international
lipid guidelines. International Atherosclerosis
Society.
Keech, A. (2003). The link between Chronic
Inflammation, Obesity and Endothelial
Dysfunction. Cardiac Society of Australia &
New Zealand.
2002
Keech, A. (2002). An update on clinical trials in
diabetes. Australian Diabetes Society.
Keech, A. (2002). Approaches to the patient with
metabolic syndrome. ASEANZ 2002.
Keech, A. (2002). Challenges in the prevention
of atherosclerosis in the Asia-Pacific region. 3rd
World Congress of the Asia-Pacific Society of
Atherosclerosis and Vascular Diseases.
Keech, A. (2002). Clinical Trials: drug or class
effects? 14th ASEAN Congress of Cardiology.
Kilian, J., Keech, A., Adams, M., Celermajer, D.
(2002). Coronary collateralization: determinants
of adequate distal vessel filling after arterial
occlusion. Coronary Artery Disease, 13(3),
155-159.
Sacks, F., Tonkin, A., Craven, T., Pfeffer, M.,
Shepherd, J., Keech, A., Furberg, C., Braunwald,
E. (2002). Coronary heart disease in patients
with low LDL-cholesterol: Benefit of pravastatin
in diabetics and enhanced role for
HDL-cholesterol and triglycerides as risk factors.
Circulation, 105(12), 1424-1428.
Kirby, A., Gebski, V., Keech, A. (2002).
Determining the sample size in a clinical trial.
Simes, R., Furberg, C., Braunwald, E., Davis, B.,
Ford, I., Tonkin, A., Shepherd, J., Keech, A.
(2002). Effects of pravastatin on mortality in
patients with and without coronary heart disease
across a broad range of cholesterol levels.
European Heart Journal, 23(3), 207-215.
Keech, A., Neal, B., MacMahon, S., Ohkubo, T.,
Brnabic, A., Tonkin, A. (2002). Effects of the
vasopeptidase inhibitor, omapatrilat, in 723
patients with coronary heart disease. Journal Of
The Renin-Angiotensin-Aldosterone System, 3(4),
270-276.
Keech, A. (2002). Evidence-based clinical
practice in diabetes. European Association of
Diabetes Societies.
Keech, A. (2002). HDL cholesterol: a new
therapeutic target for CHD prevention. 3rd
World Congress of the Asia-Pacific Society of
Atherosclerosis and Vascular Diseases.
Simes, R., Kirby, A., Keech, A., Hague, W.,
MacMahon, S., Hunt, D., Tonkin, A., Alyward,
P., Colquhoun, D., Glasziou, P., et al (2002).
Long-term effectiveness and safety of pravastatin
in 9014 patients with coronary heart disease and
average cholesterol concentrations: the LIPID
trial follow up. The Lancet, 359, 1379-1387.
Keech, A., Gebski, V. (2002). Managing the
resource demands of a large sample size in
clinical trials: can you succeed with fewer
subjects? Medical Journal of Australia, 177(8),
437-439.
Collins, R., Armitage, J., Parish, S., Sleight, P.,
Peto, R., Meade, T., Youngman, L., Buxton, M.,
de Bono, D., George, C., Keech, A., Lindley, R.,
et al (2002). MRC/BHF Heart Protection Study
of antioxidant vitamin supplementation in 20 536
high-risk individuals: a randomised
placebo-controlled trial. The Lancet, 360, 23-33.
Collins, R., Armitage, J., Parish, S., Sleight, P.,
Peto, R., Meade, T., Youngman, L., Buxton, M.,
de Bono, D., George, C., Keech, A., Lindley, R.,
et al (2002). MRC/BHF Heart Protection Study
of cholesterol lowering with simvastatin in 20
536 high-risk individuals: a randomised
placebo-controlled trial. The Lancet, 360(9326, 6
July 2002), 7-22.
Keech, A. (2002). New insights from the Heart
Protection Study. Asian Congress of Cardiology.
Asian Congress of Cardiology.
Publications for Anthony Keech
Keech, A. (2002). Principles of prospective
meta-analysis. Clinical Trials Symposium.
Beller, E., Gebski, V., Keech, A. (2002).
Randomisation in clinical trials. Medical Journal
of Australia, 177(10), 565-567.
Simes, R., Keech, A., et, A. (2002). Randomized,
placebo-controlled trial of titrated intravenous
lamifiban for acute coronary syndromes.
Circulation, 105(3), 316-321.
Keech, A. (2002). Rationale, results and
implications of the Heart Protection Study.
Malaysian Medical Society Meeting.
Keech, A. (2002). Recent advances in clinical
trials for treatment of atherosclerosis in diabetes.
Australian Health & Medical Research Congress
2002.
Simes, R., Marschner, I., Hunt, D., Sullivan, D.,
Colquhoun, D., Hague, W., Stewart, R., Keech,
A., Thompson, P., White, H., et al (2002).
Relationship between lipid levels and clinical
outcomes in the long-term intervention with
pravastatin in ischemic disease (LIPID) trial: to
what extent is the reduction in coronary events
with pravastatin explained by on-study lipid
levels? Circulation, 105(10), 1162-1169.
Richie, G., Keech, A., Yamamoto,, A.,
Nakamura, H., Hosoda,, S., Nobuyoshi,, M.,
Matsuzaki, M., Tan, C., Mabuchi, H., Horibe, H.,
et al (2002). Risk factors for coronary heart
disease in the Japanese - Comparison of the
background of patients with acute coronary
syndrome in the ASPAC study with data
obtained from the general population. Journal of
Atherosclerosis and Thrombosis, 9(4), 191-199.
Pfeffer, M., Keech, A., Sacks, F., Cobbe, S.,
Tonkin, A., Byington, R., Davis, B., Friedman,
C., Braunwald, E. (2002). Safety and tolerability
of pravastatin in long-term clinical trials.
Circulation, 105(20), 2341-2346.
Brighton, J., Gebski, V., Keech, A. (2002).
Specifying interventions in a clinical trial.
Medical Journal of Australia, , 281-282.
Gebski, V., Marschner, I., Keech, A. (2002).
Specifying objectives and outcomes for clinical
trials. Medical Journal of Australia, 176(10),
491-492.
2001
Ritchie, G., Keech, A. (2001). Asia-Pacific
collaboration on coronary heart disease risk
factor intervention: study desing and methods.
Heart, Lung and Circulation, 10, 24-29.
Hughes, C., Keech, A., Cox,, N. (2001).
Myocardial infarction due to saphenous vein
graft compression by an extracardiac mass.
Heart, Lung and Circulation, 10, 35-37.
Gebski, V., Beller, E., Keech, A. (2001).
Randomized controlled trails: elements of a good
study. Medical Journal of Australia, 175,
272-274.
Ghersi, D., Gebski, V., Keech, A. (2001).
Scientific background and rationale for a
randomised controlled trial. Medical Journal of
Australia, 175(7), 386-386.
Keech, A., Gebski, V. (2001). Selecting
participants for clinical trials. Medical Journal of
Australia, 175(9), 490-491.
2000
Miller, O., Tang, S., Keech, A., Pigott, N.,
Beller, E., Celermajer, D. (2000). Inhaled nitric
oxide and prevention of pulmonary hypertension
after congenital heart surgery: a randomised
double-blind study. The Lancet, 356(9240),
1464-1469.